Literature DB >> 3390835

Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

G A Kune1, S Kune, L F Watson.   

Abstract

The associations between colorectal cancer risk and several chronic illnesses, operations, and various medications were examined in 715 colorectal cancer cases and 727 age/sex-matched controls in data derived from a large, comprehensive, population-based study of this cancer conducted in Melbourne, Australia. There was a statistically significant deficit among cases of hypertension, heart disease, stroke, chronic chest disease, and chronic arthritis and a statistically significant excess of "hemorrhoids" among cases, and all of these differences were consistent for both colon and rectal cancer and for both males and females. Although no statistically significant differences were found for other cancers, there were twice as many breast cancers among cases (16) than among controls and also there were 9 uterine cancers among cases and only 2 among controls. There was a statistically significant deficit among cases in the use of aspirin-containing medication and vitamin supplements, and this was consistent for both colon and rectal cancer and for both males and females. There was a statistically significant excess of large bowel polypectomy among cases. The modeling of these significant associations simultaneously in a logistic regression equation indicated that hypertension, heart disease, chronic arthritis, and aspirin use were each independent effects and consistent for both colon and rectal cancer for both males and females and also that these effects were independent of dietary risk factors previously described in the Melbourne study. The possible relevance of these findings towards an understanding of colorectal cancer risk and etiology is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3390835

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  145 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.

Authors:  Raghib Ali; Han-Chong Toh; Whay-Kuang Chia
Journal:  Trials       Date:  2011-12-14       Impact factor: 2.279

3.  Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Dipak K Majumdar
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

4.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

5.  Are we making progress in diagnosing and preventing gastrointestinal cancers?

Authors:  Jelle Haringsma; Nicoline C M van Heel; Ernst J Kuipers
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 6.  Diabetes mellitus is an independent risk factor for colorectal cancer.

Authors:  Lei Sun; Shiying Yu
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

7.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

Authors:  Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Gary C Curhan; Charles S Fuchs
Journal:  JAMA       Date:  2005-08-24       Impact factor: 56.272

Review 8.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 9.  Translational Research in Familial Colorectal Cancer Syndromes.

Authors:  Molly M Ford
Journal:  Clin Colon Rectal Surg       Date:  2018-05-01

Review 10.  Anti-cancer activity of new designer hydrogen sulfide-donating hybrids.

Authors:  Khosrow Kashfi
Journal:  Antioxid Redox Signal       Date:  2013-06-07       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.